Editorial: Unifying the genetics, co-morbidities and management of COPD

Therapeutic Advances in Respiratory Disease

Volumn 2, Issue 3, 2008, Pages 113-117

  Wood, Alice M ^a   Stockley, Robert A ^b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; ABX IL8; ACETYLCYSTEINE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CILOMILAST; GELATINASE B; GLUTATHIONE TRANSFERASE P1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; INTERSTITIAL COLLAGENASE; LONG ACTING DRUG; MARIMASTAT; MONOCLONAL ANTIBODY; PHOSPHODIESTERASE IV; RESERPINE DERIVATIVE; RETINOIC ACID; ROFLUMILAST; SERPINE 2; SHORT ACTING DRUG; SURFACTANT PROTEIN B; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D BINDING PROTEIN;

CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMORBIDITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; GASTROINTESTINAL DISEASE; GENETIC ASSOCIATION; GENETIC CODE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFLAMMATION; LUNG FUNCTION; PATHOGENESIS; PHARMACOGENETICS; PRIORITY JOURNAL; PULMONARY REHABILITATION; SMOKING; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-AGONISTS; COMORBIDITY; HUMANS; PHARMACOGENETICS; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 67649397850     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465808092282     Document Type: Editorial

References (36)

1. Agusti, A.G. (2005). Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2(4): 367-370; discussion 371-372.
2. Bruce, C. and Thomas, P.S. (2005). The effect of marimastat, a metalloprotease inhibitor, on allergen-induced asthmatic hyper-reactivity. Toxicol Appl Pharmacol 205(2): 126-132.
3. Calverley, P.M., Burge, P.S., Spencer, S., Anderson, J.A. and Jones, P.W. (2003). Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 58(8): 659-664.
4. Celli, B.R. (2006). Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism. Proc Am Thorac Soc 3(1): 58-65.
5. Chasman, D.I., Posada, D., Subrahmanyan, L., Cook, N.R., Stanton Jr, V.P. and Ridker, P.M. (2004). Pharmacogenetic study of statin therapy and cholesterol reduction. Jama 291(23): 2821-2827.
6. Compton, C.H., Gubb, J., Nieman, R., Edelson, J., Amit, O., Bakst, A. et al. (2001). Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358(9278): 265-270.
7. Curkendall, S.M., DeLuise, C., Jones, J.K., Lanes, S., Stang, M.R., Goehring Jr, E. et al. (2006). Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 16(1): 63-70.
8. Decramer, M., Rutten-van Molken, M., Dekhuijzen, P.N., Troosters, T., van Herwaarden, C., Pellegrino, R. et al. (2005). Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 365(9470): 1552-1560.
9. Demeo, D.L., Hersh, C.P., Hoffman, E.A., Litonjua, A.A., Lazarus, R., Sparrow, D. et al. (2007). Genetic determinants of emphysema distribution in the national emphysema treatment trial. Am J Respir Crit Care Med 176(1): 42-48.
10. Fabbri, L., Pauwels, R.A. and Hurd, S.S. (2004). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary updated 2003. Copd 1(1): 105-141; discussion 103-104.
11. Gompertz, S. and Stockley, R.A. (2002). A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest 122(1): 289-294.
12. Hegab, A.E., Sakamoto, T., Saitoh, W., Massoud, H.H., Massoud, H.M., Hassanein, K.M. et al. (2004). Polymorphisms of IL4, IL13, and ADRB2 genes in COPD. Chest 126(6): 1832-1839.
13. Homma, S., Sakamoto, T., Hegab, A.E., Saitoh, W., Nomura, A., Ishii, Y. et al. (2006). Association of phosphodiesterase 4D gene polymorphisms with chronic obstructive pulmonary disease: relationship to interleukin 13 gene polymorphism. Int J Mol Med 18(5): 933-939.
14. Huang, S.L., Su, C.H. and Chang, S.C. (1997). Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med 156(5): 1436-1439.
15. Israel, E., Drazen, J.M., Liggett, S.B., Boushey, H.A., Cherniack, R.M., Chinchilli, V.M. et al. (2000). The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 162(1): 75-80.
16. Ito, I., Nagai, S., Handa, T., Muro, S., Hirai, T., Tsukino, M. et al. (2005). Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med 172(11): 1378-1382.
17. Jeffery, P.K., Venge, P., Gizycki, M.J., Egerod, I., Dahl, R. and Faurschou, P. (2002). Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J 20(6): 1378-1385.
18. Mahler, D.A., Huang, S., Tabrizi, M. and Bell, G.M. (2004). Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 126(3): 926-934.
19. Mao, J.T., Goldin, J.G., Dermand, J., Ibrahim, G., Brown, M.S., Emerick, A. et al. (2002). A pilot study of all-trans-retinoic acid for the treatment of human emphysema. Am J Respir Crit Care Med 165(5): 718-723.
20. Rabe, K.F., Bateman, E.D., O'Donnell, D., Witte, S., Bredenbroker, D. and Bethke, T.D. (2005). Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 366(9485): 563-571.
21. Rennard, S.I., Fogarty, C., Kelsen, S., Long, W., Ramsdell, J., Allison, J. et al. (2007). The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175(9): 926-934.
22. Rennard, S.I., Schachter, N., Strek, M., Rickard, K. and Amit, O. (2006). Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 129(1): 56-66.
23. Salpeter, S.R., Buckley, N.S., Ormiston, T.M. and Salpeter, E.E. (2006). Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 144(12): 904-912.
24. Sandford, A.J., Chagani, T., Weir, T.D., Connett, J.E., Anthonisen, N.R. and Pare, P.D. (2001). Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med 163(2): 469-473.
25. Schmidt, M.I., Duncan, B.B., Sharrett, A.R., Lindberg, G., Savage, P.J., Offenbacher, S. et al. (1999). Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 353(9165): 1649-1652.
26. Seitz, M., Wirthmuller, U., Moller, B. and Villiger, P.M. (2007). The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 46(1): 93-96.
27. Sevenoaks, M.J. and Stockley, R.A. (2006). Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity-a common inflammatory phenotype? Respir Res 7: 70.
28. Sin, D.D., Man, J.P. and Man, S.F. (2003). The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 114(1): 10-14.
29. Soyseth,V., Brekke, P.H., Smith, P. and Omland, T. (2007). Statin use is associated with reduced mortality in COPD. Eur Respir J 29(2): 279-283.
30. Sparano, J.A., Bernardo, P., Stephenson, P., Gradishar, W.J., Ingle, J.N., Zucker, S. et al. (2004). Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 22(23): 4683-4690.
31. Vozarova, B., Fernandez-Real, J.M., Knowler, W.C., Gallart, L., Hanson, R.L., Gruber, J.D. et al. (2003). The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum Genet 112(4): 409-413.
32. Wechsler, M.E., Lehman, E., Lazarus, S.C., Lemanske Jr, R.F., Boushey, H.A., Deykin, A. et al. (2006). beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 173(5): 519-526.
33. Wilk, J.B., Walter, R.E., Laramie, J.M., Gottlieb, D.J. and O'Connor, G.T. (2007). Framingham Heart Study genome-wide association: results for pulmonary function measures. BMC Med Genet 8 Suppl 1: S8.
34. Wood, A.M. and Stockley, R.A. (2006). The genetics of chronic obstructive pulmonary disease. Respir Res 7: 130.
35. Wtccc (2007). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447(7145): 661-678.
36. Yasmin, McEniery, C.M., O'Shaughnessy, K.M., Harnett, P., Arshad, A., Wallace, S. et al. (2006). Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. ArteriosclerThromb Vasc Biol 26(8): 1799-1805.